Literature DB >> 10886511

Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis.

H Echchakir1, M Bagot, G Dorothée, D Martinvalet, S Le Gouvello, L Boumsell, S Chouaib, A Bensussan, F Mami-Chouaib.   

Abstract

We have previously described two cytotoxic T lymphocyte clones isolated from lymphocytes infiltrating a human major histocompatibility complex class II-/class I+, CD4+ cutaneous T cell lymphoma. These clones displayed a CD4+CD8dim+ (TC5) and CD4+ CD8- (TC7) phenotype and mediated a specific major histocompatibility complex class I-restricted cytotoxic activity toward Cou-LB autologous tumor cell line. Our studies were performed to elucidate the mechanism involved in T-cell-clone-mediated cytotoxicity and to determine the cytokine profile of both the lymphoma cell line and specific cytotoxic T lymphocyte clones. The results indicate that, despite surface expression of Fas receptor on Cou-LB and Fas ligand induction on TC5 and TC7 cell membranes, the CD4+ cytotoxic T lymphocyte clones do not use this cytotoxic mechanism to lyse their specific target. The TC7 clone uses instead a granzyme-perforin-dependent pathway. Furthermore, quantitative analysis of Th1 and Th2 cytokine mRNA expression in the cutaneous T cell lymphoma cell line as well as in TC5 and TC7 clones indicated that, whereas the tumor cells display a Th2-type profile (interleukin-4, interleukin-6, and interleukin-10), the cytotoxic T lymphocyte clones express Th1-type cytokines (interferon-gamma, granulocyte macrophage colony stimulating factor, and interleukin-2). In addition, preincubation of the tumor-infiltrating lymphocyte clones with autologous tumor cells induced their activation and subsequent amplification of the Th1-type response. These results indicate a direct contribution of the malignant cells in the Th1/Th2 imbalance observed frequently in cutaneous T cell lymphoma patients and suggest their potential role in depressed cell-mediated immunity. Identification of CD4+ Th1-type cytotoxic T lymphocyte clones, the tumor antigen they recognize, and optimization of their cytokine expression profile should be useful for the design of new immunotherapy protocols in cutaneous T cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886511     DOI: 10.1046/j.1523-1747.2000.00995.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

Review 1.  The physiological role of cytotoxic CD4(+) T-cells: the holy grail?

Authors:  V Appay
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

2.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.

Authors:  Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-18       Impact factor: 12.531

3.  Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Authors:  Dannie Bernard; Michael S Ventresca; Laura A Marshall; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

4.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

Review 5.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

6.  Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.

Authors:  Sadamu Homma; Hideo Komita; Yukiko Sagawa; Tsuneya Ohno; Gotaro Toda
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

7.  Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma.

Authors:  Melania H Fanok; Amy Sun; Laura K Fogli; Vijay Narendran; Miriam Eckstein; Kasthuri Kannan; Igor Dolgalev; Charalampos Lazaris; Adriana Heguy; Mary E Laird; Mark S Sundrud; Cynthia Liu; Jeff Kutok; Rodrigo S Lacruz; Jo-Ann Latkowski; Iannis Aifantis; Niels Ødum; Kenneth B Hymes; Swati Goel; Sergei B Koralov
Journal:  J Invest Dermatol       Date:  2017-11-08       Impact factor: 8.551

Review 8.  Cytolytic CD4(+) T cells in viral immunity.

Authors:  Damien Z Soghoian; Hendrik Streeck
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

9.  Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers.

Authors:  Ke-Jun Nan; Yong-Chang Wei; Fu-Ling Zhou; Chun-Li Li; Chen-Guang Sui; Ling-Yun Hui; Cheng-Ge Gao
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

Review 10.  The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.

Authors:  Joseph S Durgin; David M Weiner; Maria Wysocka; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2020-12-22       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.